The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q4 2021 call → NOWe need to determine if management conveys that the reported results do not represent the current business — that the business has moved ahead of the reported period. Look for repeated or substantial indications. In the transcript, management discusses Q4 fiscal 2021 results. They mention momentum, but also note that they are entering fiscal 2022 with optimism. They talk about investments in new equipment (EvoCooler) that will bring benefits in the future, but they say benefits will start in the back half of fiscal 2022. They also mention that they expect some short-term margin pressure due to cost increases. They give guidance for fiscal 2022 with sales growth of 10%+ but operating income and EBITDA broadly consistent with fiscal 2021. That suggests they don't see a big jump in profitability. Do they say the reported period is stale? They say they are building momentum, but they don't explicitly say the reported numbers are behind the current business. They talk about future investments and expected benefits, but that's standard. They also mention that they are passing on price increases, but that's ongoing. The key is whether management indicates that the business as it stands today is ahead of the reported period. They mention that they are installing new equipment, but that's for future capacity. They also mention that they expect to see benefits in the back half of fiscal 2022. That's not saying the reported period is stale; it's saying future benefits are coming. They also mention that they are facing cost pressures and expect short-term margin pressure. That suggests the current period might be worse, not better. Thus, the answer is NO. The call is a conventional results-and-outlook discussion. They give guidance, but they don't say the reported numbers are behind the current business. They talk about future investments and expected benefits, but that's normal. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.